Right to Try seems to be a good step in terms of validating the drugs that companies make, assuming that it continues to use the “compassionate use” case in order to decide who gets these drugs. For patients that have no other approved option to turn to, potentially life saving drugs could be given to patients even if all known options have been exhausted. This also is a positive in the eyes of the drug maker as there can be early validation that their drug works (or not). Overall though, the decision of Right to Try is very risky for both parties. There is by no means any guarantee that the tried drug will even help; the drug may even make the situation worse for the patient. For the company as well, letting others try the drugs before it is cleared runs the risk of any failures blacklisting the company’s name in the public’s eyes, should anyone get worse or die. Should this be done, it should be, as it usually is, done in a way in which both parties are aware of the not only the positive possibilities, but the negative ones as well.